An overview of the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Program: 1997-2004.
about
Detecting imipenem resistance in Acinetobacter baumannii by automated systems (BD Phoenix, Microscan WalkAway, Vitek 2); high error rates with Microscan WalkAway.Comparative in vitro activity of Meropenem, Imipenem and Piperacillin/tazobactam against 1071 clinical isolates using 2 different methods: a French multicentre study.Hospital-acquired pneumonia in the 21st century: a review of existing treatment options and their impact on patient care.The importance and future of antimicrobial surveillance studies.Management of meningitis due to antibiotic-resistant Acinetobacter species.Surveillance for antimicrobial resistant organisms: potential sources and magnitude of bias.The use of carbapenems in the treatment of serious infections.Pharmacokinetic/Pharmacodynamic Analysis of Meropenem for the Treatment of Nosocomial Pneumonia in Intracerebral Hemorrhage Patients by Monte Carlo Simulation.Extended-spectrum beta-lactamase production is associated with an increase in cell invasion and expression of fimbrial adhesins in Klebsiella pneumoniae.Association between Virulence Factors and Extended Spectrum Beta-Lactamase Producing Klebsiella pneumoniae Compared to Nonproducing Isolates.In vitro activity of carbapenems alone and in combination with amikacin against KPC-producing Klebsiella pneumoniae.IMP-15-producing Pseudomonas aeruginosa strain isolated in a U.S. medical center: a recent arrival from Mexico.Bacterial isolates from severe infections and their antibiotic susceptibility patterns in Italy: a nationwide study in the hospital setting.
P2860
Q33418763-0A77C279-2FFC-4AEA-8547-CF678A694148Q33542819-54B63749-C871-40AF-9FD7-9CAE87014053Q36548708-EDE116CF-6893-4E6C-A94E-F8809EE6D638Q37247114-D9B43305-DDC7-4D3D-A508-0BC6FB2AB1DCQ37382976-964261D3-CF65-4AA0-9B97-89439A2438EAQ37506672-31FE897B-9021-4A39-97D9-0708DC7502CCQ37555757-DF635F22-4A9F-4ACE-B2A2-FE8258EDA893Q38693420-40B9A900-1D88-4754-B6D8-65955BAE456AQ39968965-57631EE7-A31C-4CD3-A496-083DAC7EFAADQ41072200-D92EE1D5-56DD-4A68-B7BF-4DC3A3C52992Q41840120-CF6A6154-913D-43CD-9549-96A310F2AE49Q43253677-E5C2E49B-F596-4BD6-AA66-9171322A33C0Q54447533-C61D5B3A-0276-443D-9572-BABCF2E7107F
P2860
An overview of the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Program: 1997-2004.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
An overview of the Meropenem Y ...... n (MYSTIC) Program: 1997-2004.
@ast
An overview of the Meropenem Y ...... n (MYSTIC) Program: 1997-2004.
@en
type
label
An overview of the Meropenem Y ...... n (MYSTIC) Program: 1997-2004.
@ast
An overview of the Meropenem Y ...... n (MYSTIC) Program: 1997-2004.
@en
prefLabel
An overview of the Meropenem Y ...... n (MYSTIC) Program: 1997-2004.
@ast
An overview of the Meropenem Y ...... n (MYSTIC) Program: 1997-2004.
@en
P2093
P1476
An overview of the Meropenem Y ...... n (MYSTIC) Program: 1997-2004.
@en
P2093
Caio Mendes
Philip J Turner
Robert Masterton
Ronald N Jones
P304
P356
10.1016/J.DIAGMICROBIO.2005.10.006
P577
2005-12-01T00:00:00Z